1. Home
  2. Browse
  3. HRA004707
HRA004707
   HRA004707.xlsx
Title:
YBX1 recognizes m5C modifications of CHD3 mRNA to promote HR repair and enhance platinum resistance of ovarian cancer
Release date:
2025-05-27
Description:
Platinum-based drug chemotherapy causes genetic damage and induces apoptosis in ovarian cancer cells. Enhancing the ability to resist platinum drug-induced DNA damage and apoptotic stress is critical for tumor cells to acquire for drug resistance. our study suggests that YBX1 promotes the development of platinum resistance in ovarian cancer by recognizing m5C modifications and it may be a potential target for reversing drug-resistant therapy.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA016838
Study type:
Disease Study
Disease name:
ovarian serous cystadenocarcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC000205
DAC name:
DAC of Gynecology, JSPH
Contact person:
cheng Wenjun
Email:
chengwenjun@jsph.org.cn
Description:
Data Access Committee of department of gynecology ,jiangsu provice hospital
Individuals & samples
Files
Request Data
Submitter:   cheng Wenjun / chengwenjun@jsph.org.cn
Organization:   The First Affiliated Hospital of Nanjing Medical University
Submission date:   2023-05-27
Requests:   -